The stock of TrovaGene Inc (NASDAQ:TROV) is a huge mover today! The stock increased 6.35% or $0.2 during the last trading session, hitting $3.35. About 152,393 shares traded hands. TrovaGene Inc (NASDAQ:TROV) has declined 34.51% since April 1, 2016 and is downtrending. It has underperformed by 35.73% the S&P500.
The move comes after 6 months positive chart setup for the $93.57 million company. It was reported on Nov, 3 by Barchart.com. We have $7.47 PT which if reached, will make NASDAQ:TROV worth $115.09M more.
Analysts await TrovaGene Inc (NASDAQ:TROV) to report earnings on November, 14. They expect $-0.32 EPS, up 13.51% or $0.05 from last year’s $-0.37 per share. After $-0.34 actual EPS reported by TrovaGene Inc for the previous quarter, Wall Street now forecasts -5.88% EPS growth.
TrovaGene Inc (NASDAQ:TROV) Ratings Coverage
Out of 5 analysts covering TrovaGene (NASDAQ:TROV), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. TrovaGene has been the topic of 8 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Cantor Fitzgerald on Tuesday, September 15. The firm has “Market Perform” rating given on Tuesday, March 29 by Avondale. The rating was downgraded by Leerink Swann on Tuesday, April 26 to “Sector Perform”. The company was downgraded on Monday, April 25 by Cantor Fitzgerald. The rating was downgraded by Janney Capital to “Neutral” on Friday, March 11. The stock of TrovaGene Inc (NASDAQ:TROV) has “Neutral” rating given on Monday, April 25 by Piper Jaffray. Leerink Swann initiated TrovaGene Inc (NASDAQ:TROV) on Friday, August 14 with “Outperform” rating.
According to Zacks Investment Research, “Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in 2016 Q2. Its down 0.84, from 1.65 in 2016Q1. The ratio dropped, as 8 funds sold all TrovaGene Inc shares owned while 23 reduced positions. 14 funds bought stakes while 11 increased positions. They now own 9.19 million shares or 9.18% less from 10.12 million shares in 2016Q1.
Nationwide Fund Advisors has 0% invested in the company for 19,577 shares. Princeton Capital Mngmt last reported 0.22% of its portfolio in the stock. The New York-based American Group Inc Inc has invested 0% in TrovaGene Inc (NASDAQ:TROV). Bluestein R H And accumulated 20,000 shares or 0.01% of the stock. Reilly Fincl Advisors Ltd Company holds 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV) for 2,525 shares. Lba Wealth Management Limited Liability Com, a Florida-based fund reported 5,000 shares. Tower Ltd Limited Liability Company (Trc) last reported 1,063 shares in the company. Barclays Public Limited Co reported 23 shares or 0% of all its holdings. Ameriprise Fincl Inc has invested 0% of its portfolio in TrovaGene Inc (NASDAQ:TROV). D E Shaw Co has 15,104 shares for 0% of their US portfolio. Royal Savings Bank Of Canada reported 200 shares or 0% of all its holdings. The California-based Schwab Charles Invest Management Incorporated has invested 0% in TrovaGene Inc (NASDAQ:TROV). Alliancebernstein Ltd Partnership holds 13,700 shares or 0% of its portfolio. Wells Fargo & Mn accumulated 0% or 18,965 shares. Blackrock Invest Mngmt Ltd Limited Liability Company accumulated 113,232 shares or 0% of the stock.
More notable recent TrovaGene Inc (NASDAQ:TROV) news were published by: Prnewswire.com which released: “Trovagene to Present at the BIO Investor Forum in San Francisco on October 19” on October 17, 2016, also Prnewswire.com with their article: “Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference” published on July 05, 2016, Prnewswire.com published: “Trovagene and University of Michigan Enter into Collaboration for Monitoring …” on July 06, 2016. More interesting news about TrovaGene Inc (NASDAQ:TROV) were released by: Zacks.com and their article: “Why Is Trovagene Inc. (TROV) Stock Soaring Today?” published on January 21, 2016 as well as Prnewswire.com‘s news article titled: “Trovagene Schedules Release of Second Quarter 2016 Financial Results and …” with publication date: July 26, 2016.
TROV Company Profile
Trovagene, Inc. (TrovaGene), incorporated on September 21, 2009, is a molecular diagnostic company. The Firm focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. The Company’s primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Firm has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.